An interventional study of Cardiac MRI and blood samples in Valve Heart Diseases, sponsored by Assistance Publique Hopitaux De Marseille. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Heart Valve Diseases with a site in France — 16 open to participants now, 22 under way, 1 of them phase 3. Heart Valve Diseases · France.
Among the 48 studies in Heart Valve Diseases with a site in France, this one is the 12th largest by planned enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2016, is one of 27 with no phase, reaches primary completion later than 8 of the 21 other live ones, and was the 15th registered.
557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.
Browse Heart Valve Diseases studies →16 of the 48 studies in Heart Valve Diseases with a site in France are open now. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18+
French Cardiology Society · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 65+ · Healthy volunteers
Abbott Medical Devices · Sites in France, United States, Denmark and 7 more countries
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3
First in 2002; this study’s year is marked. 3 started in 2016.
This study's planned enrollment of 316 is above the median of 100 across 314 interventional studies indexed under Heart Valve Diseases.
Median enrollment 228 across the 31 interventional studies, 800 across the 17 observational. Of the 25 that completed or were terminated, 8 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 48 have an industry lead sponsor. The 10 most frequent:
Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
Assistance Publique Hopitaux De Marseille has 1 study filed under Heart Valve Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Heart Valve Diseases with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06215378Phase 3Assistance Publique - Hôpitaux de ParisAntagonization of Heparin With Protamine Sulfate After TAVI | 2027-03-01 |
| NCT02747485Assistance Publique Hopitaux De MarseilleImpact of Diffuse Myocardial Fibrosis on the Ventricular Function in Regurgitant Left-Sided Valve Heart Diseases ( The DIFFUsE Study) | 2026-11 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 48 studies in Heart Valve Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
New strategies are needed to early detect myocardial involvement in these diseases. Histological studies showed that diffuse fibrosis and cardiomyocyte hypertrophy precede the LV remodelling (dilatation) observed by cardiac imaging. Quantification of LV diffuse myocardial fibrosis using magnetic resonance imaging (MRI) could reach this goal. Recently, contrast enhanced cardiac MRI has been used to measure the extracellular volume fraction (ECV) of the myocardium, and it has been able to detect diffuse myocardial fibrosis. In diseases in which increased collagen deposition enlarges the extra-cellular space, the ECV can act as a fibrosis index. ECV is correlated with the amount of fibrosis measured by histology. Left ventricular overloads induced by regurgitant VHD result in cardiomyocyte hypertrophy and diffuse fibrosis. Other methods can be used to estimate the degree of myocardial fibrosis such as the serum level of galectine-3 or ST2. Moreover, although the pathophysiological mechanisms leading to the occurrence of myocardial fibrosis differ in patients with various cardiac diseases, the cellular effectors of fibrotic remodelling are common and involve similar signalling pathways. At the cellular level, key progression of ventricular hypertrophy is associated with increased cardiomyocytes apoptosis and fibrosis, suggesting that these two processes are responsible for the transition.
To our knowledge, no study has analysed the impact of the rate of myocardial diffuse fibrosis, non-invasively estimated by ECV, in the risk of LV dysfunction during MR and AR, especially after surgery. The measurement of ECV could become an important tool for risk stratification in left-sided regurgitant VHD. Thus, it would provide an early marker of LV myocardial involvement before the occurrence of global remodeling, might help physicians in surgical decision, and would improve prognosis. This is an innovative original project because it uses modern imaging modalities to answer to a crucial question. The clinical implications would be important because this work would modify the international surgical indications of MR and AR in order to finally improve the prognosis of patients with this frequent heart disease. Moreover, investigators will analyze the genetic factors that can influence the myocardial reaction resulting from these regurgitations, which will improve the quality of this work and offer new future perspectives.
Investigators hypothesize that the ECV measurement could be used as an early predictor of LV dysfunction in the left-sided valve regurgitations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Cardiac MRI · Biological: blood samples · Procedure: myocardial biopsy · Genetic: blood samples
Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured
extract DNA to look for genomic mutations associated with the disease.
the rate of diffuse myocardial fibrosis
Time frame: 6 months
Correlations between ECV and the global longitudinal strain and the serum level of Galectin-3 and ST2
Time frame: 42 months
Correlations between ECV changes and genetic factors
Time frame: 42 months
correlations between ECV and the severity of the regurgitation
Time frame: 42 months
correlation between ECV and the myocardial deformation quantified by speckle tracking echocardiography (2D Strain)
Time frame: 42 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2016 (actual). Primary completion is estimated for Nov 2026, 126 months after the start.
Of 108 non-industry interventional studies with no phase under Heart Valve Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 126 months is above that.
Counting every sponsor, half of 154 studies reached it within 30 months; a quarter within 16 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique Hopitaux De Marseille →